Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29794225 | 1.00 | ATM (0.47) | ATMNPC1RAB9AMEN1KMT2A | |
| SCHEMBL28345567 | 0.83 | ATM (0.45) | ATMNPC1RAB9AMEN1KMT2A | |
| SCHEMBL30915437 | 0.79 | ALDH1A1 (0.42) | ATMNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1680562 | 0.79 | ALDH1A1 (0.42) | ATMNPC1RAB9AMEN1KMT2A | |
| SCHEMBL10373161 | 0.74 | CNR2 (0.54) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL6806663 | 0.73 | LMNA (0.42) | ATMRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL28150148 | 0.73 | MEN1 (0.40) | ATMNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4145326 | 0.71 | ATM (0.54) | ATMNPC1RAB9AMEN1KMT2A | |
| SCHEMBL538204 | 0.71 | TSHR (0.51) | ALDH1A1KDM4ECYP1A2CYP2C19HSD17B10 | |
| SCHEMBL8456760 | 0.70 | ATM (0.53) | ATMMEN1KMT2AALDH1A1WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117447847-B | Wear-resistant rubber composite material and preparation method thereof | 河北能一重型机械配件有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-117447847-A | Wear-resistant rubber composite material and preparation method thereof | 河北能一重型机械配件有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-101899003-A | Quinoline derivative-N-oxide ligand as well as preparation method and application thereof | SHANGHAI INST TECHNOLOGY | 2010-12-01 | — | — | CN | claimed |
| EP-0090173-B1 | METHOD FOR THE PREPARATION OF 2-AMINOPYRIDINS STARTING FROM N-OXIDES OF 2-PYRIDINE-CARBONIC ACIDS | LONZA AG (CH) | 1986-08-20 | — | — | EP | claimed |
| CN-117447847-B | Wear-resistant rubber composite material and preparation method thereof | 河北能一重型机械配件有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117447847-A | Wear-resistant rubber composite material and preparation method thereof | 河北能一重型机械配件有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-101899003-A | Quinoline derivative-N-oxide ligand as well as preparation method and application thereof | SHANGHAI INST TECHNOLOGY | 2010-12-01 | — | — | CN | disclosed |
| US-7601686-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601686-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2007008657-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070010455-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-11 | — | — | US | disclosed |
| US-20070010455-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-11 | — | — | US | disclosed |
| EP-0746561-B1 | QUINOLONYLCARBOXAMIDOCEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ARANDA LAB SA DE CV (MX) | 1999-04-28 | — | — | EP | disclosed |
| US-5728691-A | Quinolonylcarboxamidocephalosporin derivatives and pharmaceutical compositions containing them | LABORATORIOS ARANDA S.A. DE C.V. (MX) | 1998-03-17 | — | — | US | disclosed |
| EP-0746561-A1 | QUINOLONYLCARBOXAMIDOCEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LABORATORIOS ARANDA, S.A. DE C.V. (MX/MX) (MX) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023153-A1 | QUINOLONYLCARBOXAMIDOCEPHALOSPORIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LABORATORIOS ARANDA, S.A. DE C.V. (MX) | 1995-08-31 | — | — | WO | disclosed |
| US-4414416-A | Certain diacetyl-amino-phenolic derivatives | FISONS LIMITED (GB) | 1983-11-08 | — | — | US | disclosed |
| US-4328341-A | Process for preparing certain pyrano[3,2-g]quinoline 2,8-dicarboxylates and 4-oxo-quinoline-2-carboxylates | FISONS LIMITED (GB) | 1982-05-04 | — | — | US | disclosed |
| EP-0030423-A1 | A process for the production of 1,4-dihydro-4-oxo-quinoline-2-carboxylic acids, or salts, esters or amides thereof and intermediates therefor | FISONS plc (GB) | 1981-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010455-A1 | Hepatitis C virus inhibitors | HAVCR2, VIP, ENPEP | ATM 4247/4885NPC1 485/4885RAB9A 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.